LEXEO THERAPEUTICS ANNOUNCES REGULATORY UPDATE AND REGISTRATIONAL TRIAL DESIGN FOR LX2006 GENE THERAPY IN FRIEDREICH ATAXIA

NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, today announced that the Company has finalized the SUNRISE-FA 2 pivotal trial protocol and statistical analysis plan (SAP) intended to provide clinical evidence to support the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for gene therapy candidate LX2006 under the accelerated approval pathway in 2028.

Drugging the ferroptotic landscape of Friedreich’s Ataxia: Current paradigms and future directions

Cravin G, Cozza G. Drugging the ferroptotic landscape of Friedreich’s Ataxia: Current paradigms and future directions. Ferroptosis Oxid Stress. 2026;2:202618. doi:10.70401/fos.2026.0032 

 In the present review, we explore how FXN loss undermines cellular defenses against oxidative damage, placing a specific focus on the regulation of the lipid redox landscape. We detail the breakdown of glutathione (GSH)-dependent mechanisms, specifically highlighting the blunted Nrf2 antioxidant response and the subsequent reduced capacity of glutathione peroxidase 4. Alongside these deficits, we investigate the compensatory roles of GSH-independent rescue networks, namely ferroptosis suppressor protein 1 and mitochondrial dihydroorotate dehydrogenase. Looking toward clinical translation, we critically assess emerging pharmacological interventions designed to target these ferroptotic nodes. The potential of mitochondria-targeted iron chelators, lipoxygenase inhibitors, lipophilic radical-trapping antioxidants, and novel Nrf2 activators is evaluated to determine whether inhibiting ferroptosis can serve as a viable disease-modifying strategy. Moving forward, combinatorial “protect and restore” approaches will likely prove essential for maximizing therapeutic efficacy in FRDA.

Transitional Life Events in Friedreich Ataxia: Differential Age at Onset Perspectives

Iskandar, A., Buchholz, M., Sarwinska, D. et al. Transitional Life Events in Friedreich Ataxia: Differential Age at Onset Perspectives. Cerebellum 25, 96 (2026). doi:10.1007/s12311-026-02038-7 

 The results underscore the importance of incorporating onset-specific considerations into clinical care and support strategies. Future studies should aim to gain a deeper understanding of the psychosocial burden of FA across the lifespan. By considering the unique pathways of patients in different life stages, researchers can tailor interventions to address differing illness perceptions across various age at onset. Comparative studies across different hereditary ataxias, such as spinocerebellar ataxias, could clarify whether the onset-dependent patterns we observed are specific to FA or represent broader features of progressive ataxic disorders. Moreover, qualitative approaches should complement quantitative measures to deepen insight into patients’ lived experiences, particularly regarding interpersonal challenges and the use of assistive devices. Finally, future intervention studies should include targeted psychosocial support, counselling, or stigma-reduction strategies can mitigate the adverse impact of relationship-related life events and improve mental wellbeing in FA, especially for those with pediatric onset.